Pegozafermin clinical trials
Also written BIO89-100.
How each study uses pegozafermin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the pegozafermin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2023 | 1 |
| 2024 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
89bio, Inc. (5) · Hoffmann-La Roche (3)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test pegozafermin.
- Mar 2027A Study to Assess the Effect of Subcutaneous Injection Site on the Pharmacokinetics of Pegozafermin in Healthy ParticipantsPhase 1 · Hoffmann-La Roche
Studies
Open first, then newest update. How each study uses pegozafermin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASHRecruitingPhase 3Hoffmann-La RocheNCT06419374Written as Pegozafermin
- A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)RecruitingPhase 3Hoffmann-La RocheNCT06318169Written as Pegozafermin
- A Study to Assess the Effect of Subcutaneous Injection Site on the Pharmacokinetics of Pegozafermin in Healthy ParticipantsNot yet recruitingPhase 1Hoffmann-La RocheNCT07835243Written as Pegozafermin
- To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe HypertriglyceridemiaCompletedPhase 389bio, Inc.NCT05852431Written as Pegozafermin
- Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)CompletedPhase 289bio, Inc.NCT04929483Written as BIO89-100
- Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe HypertriglyceridemiaCompletedPhase 289bio, Inc.NCT04541186Written as Pegozafermin
- A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASHCompletedPhase 1/289bio, Inc.NCT04048135Written as Pegozafermin
- PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation CirrhosisCompletedPhase 189bio, Inc.NCT05022693Written as BIO89-100
Codes
What other systems call pegozafermin · ClinicalTrials.gg INT018150
- UNII (FDA) UO870O6MFSPEGOZAFERMINOne source FDA
- NCI Thesaurus C188638PegozaferminOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | UO870O6MFS | PEGOZAFERMIN | One source FDA |
| NCI Thesaurus | C188638 | Pegozafermin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.